摘要:
Alpha crystalline form of strontium ranelate of formula (I): characterized by its powder X-ray diffraction diagram and by a water content of from 22 to 24%. Medicinal products containing the same which are useful in the treatment of osteoporosis and arthrosis.
摘要:
A γd-Crystalline form of ivabradine hydrochloride of formula (I): characterised by its powder X-ray diffraction data. Medicinal products containing the same which are useful as bradycardics.
摘要:
A γ-Crystalline form of ivabradine hydrochloride of formula (I): characterised by its powder X-ray diffraction data. Medicinal products containing the same which are useful as bradycardics.
摘要:
A δ-crystalline form of ivabradine hydrochloride of formula (I): characterised by its powder X-ray diffraction data.Medicinal products containing the same which are useful as bradycardics.
摘要:
A βd-Crystalline form of ivabradine hydrochloride of formula (I): characterised by its powder X-ray diffraction data.Medicinal products containing the same which are useful as bradycardics.
摘要:
A βd-Crystalline form of ivabradine hydrochloride of formula (I): characterized by its powder X-ray diffraction data. Medicinal products containing the same which are useful as bradycardics.
摘要:
A β-Crystalline form of ivabradine of formula (I): characterised by its powder X-ray diffraction data. Medicinal products containing the same which are useful as bradycardics.
摘要:
β-Crystalline form of ivabradine of formula (I): characterised by its powder X-ray diffraction diagram.Medicinal products containing the same which are useful as bradycardics.
摘要:
A γd-Crystalline form of ivabradine hydrochloride of formula (I): characterised by its powder X-ray diffraction data.Medicinal products containing the same which are useful as bradycardics.
摘要:
A process for the industrial synthesis and a new crystalline form of the compound of formula (I): Medicinal products containing the same which are useful in treating disorders of the melatoninergic system.